WSGR logoWSGR logo
WSGR logo
  • Experience
  • People
  • Insights
  • About Us
  • Careers

  • Practice Areas
  • Industries

  • Corporate
  • Intellectual Property
  • Litigation
  • Patents and Innovations
  • Regulatory
  • Technology Transactions

  • Broker-Dealer
  • Capital Markets
  • Corporate Governance
  • Emerging Companies
  • Employee Benefits and Compensation
  • Energy and Climate Solutions
  • Finance and Structured Finance
  • Fund Formation
  • Greater China
  • Investment Adviser
  • Mergers & Acquisitions
  • Private Equity
  • Public Company Representation
  • Real Estate
  • Restructuring
  • Shareholder Activism
  • Tax
  • U.S. Expansion

  • Special Purpose Acquisition Companies (SPACs)

  • Environmental, Social, and Governance

  • Decarbonization Strategies
  • Energy Regulation and Competition
  • Project Development and Transactions
  • Project Finance and Tax Equity
  • Sustainability and Decarbonization
  • Transportation Electrification

  • U.S. Expansion Library and Resources

  • Post-Grant Review
  • Trademark and Advertising

  • Arbitration
  • Board and Internal Investigations
  • Class Action Litigation
  • Commercial Litigation
  • Consumer Litigation
  • Corporate Governance Litigation
  • Employment Litigation
  • Government Investigations
  • Internet Strategy and Litigation
  • Patent Litigation
  • Securities Litigation
  • Supreme Court and Appellate Practice
  • Trade Secret Litigation
  • Trademark and Copyright Litigation
  • Trial
  • White Collar Crime

  • Advertising, Promotions, and Marketing
  • Antitrust and Competition
  • Committee on Foreign Investment in the U.S. (CFIUS)
  • Export Control and Sanctions
  • FCPA and Anti-Corruption
  • FDA Regulatory, Healthcare, and Consumer Products
  • Federal Trade Commission
  • National Security
  • Privacy and Cybersecurity
  • Strategic Risk and Crisis Management

  • Antitrust and Intellectual Property
  • Antitrust Civil Enforcement
  • Antitrust Compliance and Business Strategy
  • Antitrust Criminal Enforcement
  • Antitrust Merger Clearance
  • Antitrust Litigation
  • European Competition Law
  • Third-Party Merger and Non-Merger Antitrust Representation

  • Anti-Money Laundering
  • Foreign Ownership, Control, or Influence (FOCI)
  • Team Telecom

  • Aviation
  • Biotech
  • Blockchain and Cryptocurrency
  • Clean Energy
  • Climate and Clean Technologies
  • Communications and Networking
  • Consumer Products and Services
  • Data Storage and Cloud
  • Digital Health
  • Digital Media and Entertainment
  • Electronic Gaming
  • Financial Services
  • FoodTech and AgTech
  • Fintech
  • Global Generics
  • Internet
  • Life Sciences
  • Medical Devices
  • Mobile Devices
  • Mobility
  • Semiconductors
  • Software

  • Offices
  • Events
  • Pro Bono
  • Community
  • Our Diversity
  • Our Values
  • Board of Directors
  • Management Team
  • Executive Advisory Program

  • Austin
  • Beijing
  • Boston
  • Boulder
  • Brussels
  • Hong Kong
  • London
  • Los Angeles
  • New York
  • Palo Alto
  • Salt Lake City
  • San Diego
  • San Francisco
  • Seattle
  • Shanghai
  • SOMA
  • Washington, D.C.
  • Wilmington, DE

  • Attorney Recruiting
  • Professional Staff
  • Recruiting Contacts

  • Experienced Attorneys
  • Law Students
  • Alternative Legal Careers
  • Virtual Learning Programs

  • Apply Online
  • Associates Committee
  • Benefits Snapshot
  • Career Management Center
  • Compensation and Benefits
  • Contacts
  • Launch
  • Mentoring and Feedback
  • NALP Forms
  • Professional Development
  • Work Assignments
  • Your School Alumni

  • Contacts
  • First Year Academy
  • Join a Winning Team
  • Launch and Accelerate
  • Law School Recruiting
  • NALP Forms
  • Summer Program
  • Tech Degrees
  • Your School Alumni

  • Current Openings
  • Employee Benefits Summary
  • Patent Agents & IP Specialists

At the Forefrontof Fintech.

Wilson Sonsini represented Blockstack in the first-ever offering of a cryptocurrency token to be either qualified or registered under federal securities laws of the U.S. for sale to the public.

Wilson Sonsini Goodrich & Rosati's legacy closely traces the birth and evolution of Silicon Valley.

For more than six decades, Wilson Sonsini has represented the technology pioneers associated with virtually every milestone innovation.

Today, the firm is synonymous with ushering promising, innovative companies through their business life cycle.

Read More About Us
Quick Links
  • Our Commitment to Community and Change
  • Find the right attorney

Introducing Neuron, a new platform that streamlines, automates, and digitizes the typical legal processes along a start-up’s journey

Neuron Website
Careers

We look for the best and brightest of tomorrow and develop careers from the ground up.

  • Attorney Recruiting
  • Professional Staff
  • Contacts

News and Featured Insights

Newsletters
1H 2022 Entrepreneurs Report
Bylined Articles
A Tale of Two Filers: CFIUS Report Touts Efficiency, Also Indicates CFIUS Failed to Meet Statutory Deadlines for a Large Percentage of Filed Notices
White Papers/Briefs
Energy and Climate Solutions White Paper: Federal Funding Opportunities for Scaling Climate Solutions
Leading Matters
Client Highlights
Wilson Sonsini Advises Obsidio on Its Acquisition by Boston Scientific
On August 15, 2022, Boston Scientific Corporation announced the acquisition of Obsidio, Inc., a privately-held company that has developed the Gel Embolic Material (GEM) technology used for embolization of blood vessels in the peripheral vasculature. Specific terms of the transaction have not been disclosed.
Learn More
Client Highlights
Wilson Sonsini Advises AliveCor in Series F Financing
On August 16, 2022, AliveCor, the global leader in FDA-cleared personal electrocardiogram (ECG) technology, announced its Series F Financing led by GE Healthcare. Also joining the round are NGK-NTK (through a CVC partnership with Pegasus Tech Ventures) and existing investors including Khosla Ventures, Bold Capital Partners, Qualcomm Ventures, and WP Global Partners. Wilson Sonsini Goodrich & Rosati advised AliveCor in the financing.

AliveCor will use this financing to advance its mission of becoming a premier provider of end-to-end cardiological care for patients when they are not in front of their cardiologists by introducing subscription services, KardiaCare and KardiaComplete for patients, payers and employers, and KardiaPro for physicians. These subscription services are supported by the company's personal ECG devices, including KardiaMobile, KardiaMobile 6L, and KardiaMobile Card. This financing will also allow for continued advancements in AliveCor's AI roadmap and pipeline of innovations.
Learn More
Client Highlights
Wilson Sonsini Advises Lumentum on Acquisition of IPG Photonics’ Telecom Transmission Product Lines
On August 15, 2022, Lumentum Holdings Inc. announced that it has acquired IPG Photonics' telecom transmission product lines in an all-cash transaction. According to the press release, the acquisition adds "highly complementary and differentiated transceiver product lines and ASIC capabilities" to Lumentum, which will "help expand [the] addressable market and augment [Lumentum's] technology capabilities.” Terms of the transaction were not disclosed.
Learn More
Client Highlights
Wilson Sonsini Advises BigHat Biosciences on IP and Licensing Matters Related to $75 Million Series B
On July 20, 2022, BigHat Biosciences, a biotechnology company developing safer, more effective antibody therapies for patients using machine learning and synthetic biology, announced the completion of a Series B financing of $75 million led by Section 32, with participation from new investors Amgen Ventures, Bristol Myers Squibb, Quadrille Capital, Gaingels, and GRIDS Capital. Prior investors Andreessen Horowitz, 8VC, and AME Cloud Ventures also contributed to this round. The company has raised over $100 million to date. Wilson Sonsini Goodrich & Rosati provides support in IP and licensing matters to BigHat Biosciences.
Learn More
Client Highlights
Wilson Sonsini Advises Marengo Therapeutics on Patent Matters Related to Strategic Partnership with Ipsen
On August 1, 2022, Ipsen and Marengo Therapeutics announced a strategic partnership to advance two of Marengo’s preclinical STAR platform-generated candidates into the clinic. The collaboration will leverage Marengo’s proprietary R&D expertise of a novel mechanism of T cell activation with Ipsen’s global oncology footprint for clinical development and commercialization. Under the terms of the agreement, Ipsen will make an upfront payment of $45 million, together with potential payments up to a total of $1.592 billion if all milestones are met in addition to tiered sales royalty payments. Marengo will lead the preclinical development efforts and will expense related costs until the submission of an Investigational New Drug (IND) application to the U.S. FDA. Ipsen will assume responsibilities for clinical development and commercialization.
Learn More
Client Highlights
Wilson Sonsini Advises MiroBio on Patent Matters Related to Acquisition by Gilead
On August 4, 2022, Gilead Sciences and MiroBio, a privately-held UK-based biotechnology company focused on restoring immune balance with agonists targeting immune inhibitory receptors, announced that the companies have entered into a definitive agreement pursuant to which Gilead will acquire MiroBio for approximately $405 million in cash, subject to customary adjustments. The acquisition will provide Gilead with MiroBio’s proprietary discovery platform and entire portfolio of immune inhibitory receptor agonists. MiroBio’s lead investigational antibody, MB272, is a selective agonist of immune inhibitory receptor B- and T-Lymphocyte Attenuator (BTLA) and has entered Phase 1 clinical trials, with the first patient dosed earlier this week. MB272 targets T, B and dendritic cells to inhibit or blunt activation and suppress an inflammatory immune response.
Learn More
See More Leading Matters
The Entrepreneurs Report – 1H 2022

In this latest issue of The Entrepreneurs Report, we've compiled a range of data on venture financing transactions in which the firm was involved during the first half of 2022, with the objective of identifying relevant trends in activity and valuation levels for the U.S. venture capital industry in general. This edition also includes data from Beauhurst—a searchable database of the UK's high-growth companies—on UK equity investment in 1H 2022.

Read More
  • people
  • insights
  • about us
  • careers
  • Binder
  • Alumni
  • Mailing List Signup
  • Client/Employee Login
  • Client FTP Portal
  • Privacy Policy
  • Terms of Use
  • Accessibility
WSGR logo
Twitter
LinkedIn
Facebook
Instagram
Youtube
Copyright © 2022 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.